| A | 2-amino-4-(methylseleno)-butanoic acid |
|--|--|
| Absorption, 228-230, 235-237, 245 | see selenomethionine |
| ACE-inhibitory peptides, 212–218 | Amlaor, 309 |
| dairy products, 48, 247 | Amorphophallus konjac, 288 |
| fermented cheese, 247 | Amorphous calcium phosphate (ACP), 235, 237 |
| milk protein-derived, 209, 210, 211 | AMP see advanced Maillard products |
| spontaneously hypertensive rat, 232-234 | Angiotensin I-converting enzyme see ACE |
| trypsin produced, 240 | Animal feed supplements, 92-94 |
| Acetylation, 3 | Animal proteins, 216, 218 |
| Aconitum napellus, 150 | Anti-inflammatory activity |
| ACP see amorphous calcium phosphate | Echinacea, 155-156 |
| Advanced Maillard products (AMP), 28, 35 | lactoferrin, 187-188 |
| Adverse reactions, Echinacea, 160-161 | Antibodies see immunoglobulins |
| AFP see antifreeze proteins | Anticariogenic properties of milk proteins, 50 |
| Aged garlic extract (AGE), 298, 319 | Antifreeze proteins (AFP), 205-206 |
| Aggregation, 35-37, 51-52 | Antigenicity, 41 |
| AGP see arabinogalactan-protein | Antihypertensive activity |
| AIDS see HIV/AIDS | ACE-inhibitory peptides, 232-234 |
| Alcohols, 11, 12, 14 | fermented dairy products, 245-247 |
| Algae, 79–80, 297 | whey protein effect, 182 |
| Alkamides, 115, 117–129, 144, 146, 156 | Antimicrobial activity |
| Alkylation, 3 | see also microorganisms; viruses |
| Allergenicity, 40–41, 43, 248 | Echinacea, 154-155 |
| Allicin, 298 | Maillard reaction, 33, 34–35 |
| Allium cepa, 298 | milk protein-derived bioactive peptides, 47, |
| A. sativum, 298, 318–322 | 49, 186–187, 210, 211, 222, 223, 235 |
| S-allyl cysteine (SAC), 298, 319 | Antioxidants |
| Amadori products, 27–28 | Echinacea, 155-156, 161-164 |
| Amidation, 3 | flavonoids, 292-294 |
| Amino acids | β-lactoglobulin after glycation, 33, 34 |
| see also individual amino acids | peptides, 226 |
| bitterness, 41–42 | Antithrombotic peptides, 47, 49, 210, 218 |
| incorporation by transglutaminase into | Antiviral activity |
| proteins, 43 | Echinacea, 154–155 |

| lactoferrin, 186–187 | Camellia chinensis, 292 |
|---|---|
| milk proteins, 25–27, 186–187 | Campesterol, 289, 291 |
| Apis mellifica, 150 | Cancer, 180-181, 304 |
| Apium graveolens, 311–312 | Candida albicans, 154–155 |
| Apocynum venetum, 304–305 | CAP see caffeic acid phenols |
| Arabinogalactan-protein (AGP), 140-142 | Capparis decidua, 289 |
| Arabinose, 28, 29, 30, 31, 32, 34 | Carbamylation, 3 |
| Arginine, 5–6, 8, 10 | Carboxymethylation, 4 |
| Arjun, 309–310 | Caries, 50, 235, 237 |
| Arnica montana, 150 | β-carotene, 282, 287, 292 |
| Artichoke, 314 | Casein phosphopeptide see caseinophospho- |
| Aspergillus tereus, 297 | peptide fragments |
| Atherosclerosis | Caseinomacropeptide see glycomacropeptide |
| garlic, 320–322 | Caseinophosphopeptide (CPP) fragments |
| herbs, 322–324 | bioactive peptides as ingredients, 245 |
| plant products, 278-279, 292-294, 296, 298 | isolation, 241 |
| Autoimmune conditions, 160 | mineral-binding, 49-50, 224-225, 235-237 |
| Avena sativa, 288 | Caseins |
| Ayurvedic medicines, 305–308, 318 | see also milk proteins |
| , | α_{s1} -casein, transglutaminase gelatinization, |
| В | 43 |
| Bacteriophage replication, 25-27 | β-casein |
| Baptisia tinctoria, 150 | esterification and ester derivatives, 15, |
| Bengal gram, 305 | 20, 22–23 |
| Beverages, 245–247 | hydrolysis studies, 54–57 |
| Bilberry fruit, 314 | peptic hydrolysis, 16–17 |
| Bioactive proteins and peptides | transglutaminases, 44 |
| bioactive food proteins, 176–206 | к-casein |
| bioactive peptides from food proteins, | glycomacropeptide bioactivity, 191–194 |
| 207–237 | immunosuppressive effect, 180 |
| research needs, 248–249 | bioactive peptides and proteins, 177, 178, |
| safety implications, 247–248 | 180, 207–208, 209–210 |
| technological production processes, | cross-linked/native nutritional comparison, |
| 237–247 | 45 |
| Bioavailability, selenomethionine, 88–90 | phosphorylation, 4–8, 9 |
| Biosynthesis, selenomethionine, 78, 79 | proteolytic modification, 38–40 |
| Bitter peptides, 41–42, 227 | Casokinins, 213 |
| Bovine colostrum, 178–179, 195–196, 201–202 | Casomorphins, 45, 46, 48, 207–208, 230, 231 |
| Bovine haemoglobin, 212 | Casoplatelins, 47, 49 |
| Bovine milk, 40, 178–179, 218–220 | Casoxins, 45, 46, 48 |
| Browning reactions see Maillard reactions | Catechins, 286, 294–295 |
| Dio wining reactions see mannatur reactions | Celery, 311–312 |
| C | Cereals, 203–204 |
| Caffeic acid phenols (CAP), 116, 117–118, | Channa, 305 |
| 129–140, 144–147, 153, 154–156 | Chicory, 312 |
| Calcium | Chitosan, 289 |
| absorption, 235–236 | Chlorogenic acid, 116, 132–133, 135, 155 |
| amorphous calcium phosphate, 235, 237 | Cholesterol, 289–292 |
| mineral-binding peptides, 49–50, 224–225, | see also hypercholesterolemia |
| 245 | Chromatography, selenomethionine, 75–76 |
| 210 | emematography, selenomethomne, 15-10 |

| Cicer arietinum, 305 | 1,2-dimethyl hydrazine (DMH), 299, 304 |
|--|--|
| Cichoric acid, 116, 129-134, 135-140, 144, | Dimethylselenide (DMSe), 79, 80 |
| 145, 153, 154 | Diosgenin, 291 |
| Cichorium intybus, 312 | Disulfide interactions, 51–52 |
| Citrus flavonoids, 283, 294 | DMH see 1,2-dimethyl hydrazine |
| Citrus paradisi, 294 | DMSe see dimethylselenide |
| Clastogenic activity, 33 | DNA, esterified milk proteins, 23, 25–27 |
| Clinical evaluations, <i>Echinacea</i> , 156–159 | Drinks see beverages |
| Co-denaturation, 35–37 | DSHEA see Dietary Supplement Health and |
| Cold, common, 156–159 | Education Act of 1994 |
| Colon cancer, 304 | |
| Colostrum, 178–179, 195–196, 201–202 | ${f E}$ |
| Commiphora mukul, 291, 305-308 | EAI see emulsifying activity index |
| Common cold, 156–159 | Echinacea, 113–173 |
| Coraindrum sativum, 299, 304 | additive, 161–164 |
| Cordyceps sinensis, 297 | adverse reactions, 160–161 |
| Coriander seed, 299, 304 | alkamides, 115, 117-119 |
| Coronary artery diseases (CAD), 279 | anti-inflammatory activity, 156 |
| Cows, 92–93 | collection/analysis, 119–122 |
| Cow's milk see bovine milk | isolation/structure, 122–124 |
| COX see cyclooxygenase | quality assurance, 146 |
| CPP fragments see caseinophosphopeptide | recovery/stability, 124–129 |
| fragments | standardization, 144 |
| Crataegus spp., 313 | anti-inflammatory activity, 155–156 |
| Cross-linking of proteins, 42–45, 53 | antimicrobial activity, 154–155 |
| Curcuma longa, 308–309 | antioxidant activity, 155–156, 161–164 |
| Curd 52 | antiviral activity, 154–155 |
| Cyclooxygenase (COX) inhibitors, 156 | autoimmune conditions, 160 |
| Cynara scolymus, 314 | biological activities, 148-156 |
| Cynarin, 116, 132, 155 | caffeic acid phenols, 116, 117–118 |
| Cytokines, 149–153 | collection/analysis, 129–133 |
| Cytomegalovirus, 25 | isolation/structure, 133-135 |
| Cytotoxicity, 33, 35 | quality assurance, 145–147 |
| -,,,, | recovery/stability, 135–140 |
| D | standardization, 144–145 |
| DADS see diallyl disulfide | clinical evaluations, 156–159 |
| Dairy cows, 92–93 | glycoproteins, 140–144 |
| Dairy proteins see caseins; milk proteins; whey | history of usage, 113–117 |
| proteins | HIV/AIDS, 154, 160 |
| Defense mechanism <i>see</i> immune system | immunology, 148–153 |
| Denaturation, 35–37 | ketoalkenes/ketoalkynes, 115, 117–118, |
| Diabetes, 311 | 121, 124 |
| Diallyl disulfide (DADS), 298, 319 | leukemia, 150–151 |
| Diet | phagocytosis, 149–150, 151–152, 154, 158 |
| bioactive peptides and proteins, 175–276 | polysaccharides, 117, 140–144, 152–153, |
| fibers, 282, 284, 288–289 | 154–155, 156 |
| hypercholesterolemia, 281 | pregnancy, 160 |
| Dietary Supplement Health and Education Act of | product regulations, 147–148 |
| 1994 (DSHEA), Echinacea, 148 | quality assurance, 145–147 |
| Digestion, 228–230, 239–241 | species classification, 113–114 |
| | |

| standardization, 144-145 | Fractionation techniques, 237–239 |
|---|---|
| toxicology, 159-161 | Functional foods |
| upper respiratory infections, 156–159 | bioactive peptides, 245-247 |
| Eggs | Echinacea, 113–173 |
| bioactive peptides and proteins, 202–203, | Functional properties |
| 217, 221 | chemical modification, 2–37, 58 |
| selenium supplementation, 94 | enzymatic protein processing, 38–40 |
| Emblica officinalis, 309 | esterification, 17–23 |
| Emulsification | genetic engineering of milk proteins and |
| esterification of milk proteins, 17-18, | proteases, 50–57 |
| 23, 24 | β-lactoglobulin glycation, 30–32 |
| β-lactoglobulin after glycation, 32 | milk protein modification, 1–71 |
| proteolytic modification, 38–39, 40 | Fungal polysaccharides, 282, 297 |
| transglutaminase cross-linking of milk | Furostanols, 286, 291–292 |
| proteins, 44 | 1 4105(411015, 200, 2)1 2)2 |
| Emulsifying activity index (EAI), 6–8, 10 | G |
| English horseradish, 304 | Garlic, 298, 318–322 |
| Enzymes | Gastrointestinal (GI) tract |
| bioactive peptide production, 239–241 | bioactive peptides, 228–230, 231 |
| milk protein processing, 37–50, 58–59 | glycomacropeptide, 192–193 |
| recombinant, 53–57 | immune milk preparations, 197–200 |
| selenomethionine analysis, 76 | Gelation |
| selenomethionine degradation, 86–87 | β-lactoglobulin, 52–53 |
| Esterification, 2–4, 10–27 | proteolytic modification, 39, 40 |
| Ethanol, 12–14, 15 | transglutaminase, 43–44 |
| | _ |
| Eupartorium perfoliatum, 150 | Generally recognized as safe (GRAS), 116, 148 |
| Evening primrose, 312 | Genetic engineering, 50–57 |
| Excretion of selenomethionine, 85–86 | GI tract see gastrointestinal tract |
| Exorphins see opioid peptides | Gingko biloba, 292 |
| F | γ-glutamylization, 42 |
| F | Glutathione, 181 |
| Familial hypercholesterolemia (FH), 290 | Glutathione peroxidases (GSH-Px), 87–88, 89, |
| Fatty acids, 284, 296 | 90-91 |
| Fenugreek, 310–311 | Glycation of β-lactoglobulin, 27–35 |
| Fermented dairy products, 242–247 | Glycine max, 314–315 |
| FH see familial hypercholesterolemia | Glycomacropeptide (GMP) |
| Fibers, 282, 284, 288–289 | bioactivity, 178, 180, 182, 191–194 |
| Fibrates, 280–281 | immunosuppressive effect, 180, 182, 193 |
| Ficus glomerata, 289 | Glycoproteins, 140–144 |
| F. religiosa, 289 | GMP see glycomacropeptide |
| Flavonoids, 282, 283, 292–294 | Grapes, 313 |
| Flavor, 226–227 | GRAS see generally recognized as safe |
| Flaxseed, 317–318 | Grifolia frondosa, 288 |
| Foaming | Growth factors, 179, 201–202 |
| β-lactoglobulin after glycation, 32 | GSH-Px see glutathione peroxidases |
| phosphorylated caseins, 8, 9 | Guanidination, 3 |
| proteolytic modification, 39–40 | Guar gum, 283 |
| Food processing, 242–245 | Guggul, 305–308 |
| Food supplements, 74, 91–94 | Guggulipid, 283, 291, 305-308 |
| Foods for Specified Health Use (FOSHU), 148 | Guggulsterones, 286, 291, 307 |

| Н | Curcuma longa, 308–309 |
|---|--|
| Haemoglobin, 212 | Cynara scolymus, 314 |
| Hawthorn, 313 | Emblica officinalis, 309 |
| HDL see high density lipoprotein | <i>Glycine max</i> , 314–315 |
| Health Canada, 116, 147–148 | Inula racemosa, 309 |
| Heparin, 282 | Linum usitatissimum, 317-318 |
| Herbs, hypercholesterolemia, 298-324 | Monascus purpureus, 316 |
| High density lipoprotein (HDL), 278-281, 290, | Moringa oliefera, 304 |
| 295-296 | Oenothera biennis, 312 |
| Histidine, 6 | Phyllanthus niruri, 299 |
| HIV/AIDS, 154, 160 | Plantago psyllium, 315-316 |
| HMG-CoA reductase, 279–280, 282, 291 | Portulaca oleracea, 313 |
| Hordeum vulgare, 288 | Silybum marianum, 316–317 |
| Horseradish, English, 304 | Terminalia arjuna, 309-310 |
| Human milk, 40 | Trigonella foenumgraecum, 310-311 |
| Hydrolysis | Vaccinium myrtillus, 314 |
| bioactive peptide production, 239–241 | Vitis vinifera, 313 |
| bitter peptide formation, 41-42, 227 | indoles, 282, 296 |
| β-casein ester derivatives, 16–17 | lycopene, 282, 285, 292 |
| DNA complexes with esterified proteins, | mevinolin, 282, 297 |
| 26–27 | plant products, 278–279, 281–324 |
| enzymatic protein processing, 38-40 | propionate, 297 |
| α -lactalbumin ester derivatives, 16, 17 | resveratrol, 286, 296–297 |
| β-lactoglobulin ester derivatives, | rice bran oil, 297 |
| 10, 15–16 | saponins, 284, 295 |
| recombinant enzyme design, 54–57 | soybean protein, 282, 295–296 |
| selenomethionine analysis, 76–77 | sterols, 282, 284–287, 289–292 |
| whey proteins, 40–41 | sulfur-containing compounds, 282, 285, |
| (β-hydroxy-β-methylglutaryl)-CoA | 298 |
| see HMG-CoA | tea polyphenolics, 283, 294–295 |
| 4-hydroxyisoleucine, 311 | unsaturated fatty acids, 284, 296 |
| Hypertension see antihypertensive activity | Hypolipidemia |
| Hypocholesterolemia, 277-338 | current therapies, 279–281 |
| algal extracts, 297 | garlic, 318, 320-322 |
| β-carotene, 282, 287, 292 | herbs, 306-7, 322-324 |
| citrus flavonoids, 283, 294 | plant products, 278-279 |
| current therapies, 279-281 | |
| dietary factors, 281 | I |
| dietary fibers, 282, 284, 288-289 | Ice-binding proteins, 205-206 |
| flavonoids, 282, 283, 292-294 | IFN see interferons |
| fungal polysaccharides, 282, 297 | IGF-I/IGF-II see insulin-like growth factors |
| herbs, 298–324 | IL see interleukins |
| Allium sativum, 318-322 | Ileum-contracting peptides, 225 |
| Apium graveolens, 311-312 | Immobilized enzymes, 53-54 |
| Apocynum venetum, 304–305 | Immune milk preparations, 197-200 |
| Cicer arietinum, 305 | Immune system |
| Cichorium intybus, 312 | bioactive peptides, 209, 210, 218–221, |
| Commiphora mukul, 305–308 | 234–235 |
| Coraindrum sativum, 299, 304 | к-casein, 180 |
| Crataegus spp., 313 | Echinacea, 148-153 |

| glycomacropeptide, 180, 182, 193 | Lactoferrin |
|---|--|
| lactoferrin, 187–188 | antimicrobial activity, 186–187, 222, |
| selenomethionine, 90–91 | 223 |
| Immunoglobulins | biological functions, 178, 185–187 |
| biological importance, 178, 195-196 | commercial applications, 189 |
| commercial utilization, 197 | immune system, 187–188 |
| milk and colostrum, 195-196 | inflammatory response, 187-188 |
| structure and functions, 194-195 | isolation, 239 |
| technological properties, 196-197 | milk protein antiviral effects, 25 |
| Immunopeptides | nutritional significance, 188-189 |
| bovine milk, 218–220 | structural and biochemical properties, |
| milk proteins, 48-49 | 184-185 |
| proline-rich polypeptides, 220-221 | technological properties, 185 |
| Indoles, 282, 296 | β-lactoglobulin (β-lg) |
| Inflammatory response, lactoferrin, | allergenicity reduction by hydrolysis, 40 |
| 187–188 | bioactivity, 178, 183–184 |
| Injection, selenomethionine organ distribution | DNA complexes with esterified derivatives, |
| after, 84–85 | 23, 25, 26–27 |
| Insulin-like growth factors (IGF-1/IGF-II), 201 | esterification and ester derivatives, 10, |
| Intake recommendations for selenium, | 11-14, 18-20, 23, 25 |
| 101–102 | gelation, 52–53 |
| Interferons (IFN), 152 | glycation under mild conditions, 27–35 |
| Interleukins (IL), 149–150, 152–153 | isolation, 238 |
| Inula racemosa, 309 | limited proteolysis, 39 |
| Inulin, 142, 283 | oil-water interface, 17 |
| Iron, 184, 185, 186, 236–237 | phosphorylation, 8, 10 |
| Isoflavones, 283 | thermal structural modifications, 35–37 |
| Isolation techniques, bioactive proteins and | thermostability, 51–52 |
| peptides, 237–239 | Lactokinins, 214 |
| Isracidin, 235 | Lactoperoxidase, 179, 182, 189-191, 239 |
| | Lactorphins, 45, 46, 208, 211, 212 |
| J | α-lactulosyllysine, 28 |
| Juglans vigra, 288 | LDL see low density lipoprotein |
| Vilgitiis 71874, 200 | Leukemia, 150–151 |
| K | β-lg see β-lactoglobulin |
| Ketoalkenes/ketoalkynes, 115, 117–118, 121, | Limited proteolysis, 38–40 |
| 124 | Linum usitatissimum, 317–318 |
| 121 | Lipoxygenase (LOX), 293 |
| L | Listeria monocytogens, 154–155 |
| α-la see α-lactalbumin | Low density lipoprotein (LDL), 279–281, |
| Lachesis muta, 150 | 288–296 |
| α -lactalbumin (α -la) | LOX see lipoxygenase |
| bioactivity, 178, 182–183 | LP-system, 189–191 |
| DNA complexes with esterified derivatives, | see also lactoperoxidase |
| 23, 25, 26–27 | Luobuma, 304–305 |
| esterification and ester derivatives, 14, 16, | Lycopene, 282, 285, 292 |
| 17, 20, 21, 23, 25 | Lycopene, 282, 283, 292 Lymphocytes |
| isolation, 238 | * * * |
| | casein, 177, 180 |
| thermal structural modifications, 35–37 | immunopeptides, 219–220 |
| Lactoferricin, 47, 235 | in vivo whey proteins, 182 |

| Lysine, 5–6, 8, 10, 27–28 | N |
|---|---|
| Lysozyme (LZM), 179, 202, 203 | N-esterification see esterification |
| | Nanofiltration, 238 |
| \mathbf{M} | Nardostachyas jatamansi, 308 |
| Maillard (nonenzymatic browning) reactions, | Naringin, 287, 294 |
| 27-35 | Natural killer (NK) cells, 149-151 |
| Marine phytoplankton, 79-80 | Nervous system, 230–231 |
| Membrane separation, 237, 238, 239, 241 | Nicotinic acid, 279 |
| Metabolism, selenomethionine, 86–91 | NK see natural killer |
| Methanol, 11, 12, 14, 15 | Nonenzymatic browning reactions see Maillard |
| Methionine | reactions |
| see also selenomethionine | Nutraceuticals, 59 |
| selenomethionine comparison, 75 | |
| selenomethionine replacement in proteins, | 0 |
| 82-83 | O-esterification see esterification |
| Methionine selenoxide, 75 | Oenothera biennis, 312 |
| Mevinolin, 282, 297 | Opioid peptides, 207–212 |
| Microbial transglutaminase see transglutaminase | milk proteins, 45, 46, 48 |
| Microorganisms | nervous system effects, 230-231 |
| see also antimicrobial activity | Organoleptic perception, 18 |
| bioactive peptides, 210, 211, 222-223, | Organs, selenomethionine, 83-85 |
| 235 | Oryza sativa, 297 |
| glycomacropeptide, 192-3 | Oxidation, 4 |
| immune milk preparations, 197-200 | |
| lactoferrin, 186-187 | P |
| LP-system, 189-191 | PBMC see peripheral mononuclear cells |
| Milk | Pepsinolysis see peptic hydrolysis |
| allergenicity, 40 | Peptic hydrolysis |
| bovine, 40, 178-179, 218-220 | β-casein ester derivatives, 16–17 |
| LP-system preservation, 191 | α -lactalbumin ester derivatives, 16, 17 |
| Milk proteins | β-lactoglobulin ester derivatives, 10, 15–16 |
| see also caseins; individual milk proteins; | Peptides |
| whey proteins | absorption, 228-230 |
| bioactive peptides and proteins, 176-202, | bioactive proteins and, 175-276 |
| 207–212, 233 | bitterness, 41–42 |
| chemical modification, 2-37, 58 | food protein derived bioactive, 207-237 |
| enzymatic processing, 37–50 | fraction enrichment, 239-241 |
| function, 176 | Peripheral mononuclear cells (PBMC), 153 |
| functional and biological property | pH |
| improvement, 1–71 | esterified milk protein functional properties, |
| genetic engineering, 50–57 | 17–23 |
| liberation of bioactive peptides during | whey protein denaturation, 35, 36, 37 |
| processing, 242–245 | pH-solubility curves |
| Milk thistle, 316–317 | β-lactoglobulin glycation, 30–32 |
| Mineral-binding peptides, 49–50, 209, | phosphorylated caseins, 6, 7 |
| 223–225, 235–237, 245 | Phagocytosis, 149-150, 151-152, 154, 158 |
| Monascus purpureus, 316 | Phenolic acids, 133 |
| Monotes engleri, 294 | Phenylpropanoid glycosides, 116 |
| Moringa oliefera, 304 | Phosphoamidation, 5−6 |
| Muscles, 83–84 | Phosphorylation, 2–10 |
| | |

| Phyllanthus niruri, 299 | Q |
|--|--|
| Phytoplankton, 79–80 | Quality assurance, 145–147 |
| Phytosterols, 284, 289–292 | Quinyl esters of caffeic acid, 116 |
| Pigs, 93, 95–96 | |
| Plantago psyllium, 315–316 | R |
| Plantain, 315–316 | Rafuma, 304–305 |
| Plants | Rats, spontaneously hypertensive, 232-234 |
| see also individual plant names | Recombinant enzymes, 53–57 |
| herbs, 298–324 | Red yeast rice, 316 |
| proteins, 203-205, 214-215 | Reductive alkylation, 3 |
| seleniferous, 74, 77-79 | Regulations, Echinacea, 147-148 |
| Polyphenol oxidase (PPO), 135-139 | Resveratrol, 286, 296-297 |
| Polyphenolics, 283, 292-295, 296-297 | Retention, selenomethionine, 85-86 |
| Polysaccharides | Ribose, 28, 29, 30, 31, 32, 34 |
| Echinacea, 117, 140-144, 152-153, | Rice bran oil, 297 |
| 154–155, 156 | |
| hypercholesterolemia, 282, 297 | \mathbf{S} |
| Portulaca oleracea, 313 | SAC see S-allyl cysteine |
| Poultry, 93–94 | Saccharomyces cerevisiae see Se yeast |
| PPO see polyphenol oxidase | Sajna, 304 |
| Pregnancy, 160 | Saponins, 284, 295 |
| Probucol, 281 | SDS-PAGE |
| Product regulations, <i>Echinacea</i> , 147–148 | casein phosphorylation, 5 |
| Production processes, bioactive proteins and | esterified β-caseins, 16–17 |
| peptides, 237–247 | esterified α -lactalbumin, 14, 17 |
| Proline-rich polypeptides (PRP), 220–221 | β-lactoglobulin glycation, 29 |
| Propanol, 14, 15 | Se yeast, 74, 80–82 |
| Propionate, 297 | animal feed supplement, 92–94 |
| Prosopsis cinceria, 289 | selenomethionine determination, 76 |
| Proteases, genetic engineering, 54–57 | Selenate/selenite |
| Proteins | see also selenomethionine |
| absorption, 228–230 | inorganic Se yeast preparations, 74, 82 organ distribution after injection, 84 |
| animal, 216, 218 | toxicity, 78, 95, 96, 97 |
| bioactive peptides and, 175–276 cross-linking, 42–45, 53 | uptake, retention and excretion, 85 |
| esterification, 10–27 | Selenium |
| milk, 1–71 | reference values, 99–100 |
| phosphorylation, 2–10 | requirements and recommended dietary |
| plant, 203–205, 214–215 | intakes, 101–102 |
| selenomethionine replacement of | supplementation, 74, 91–94, 100 |
| methionine, 82–83 | uptake, retention and excretion, 85 |
| Proteolysis | Selenoenzymes, 87–88, 89 |
| bitter peptide formation, 41–42 | Selenomethionine (SeMet), 73–112 |
| functional properties, 38–40 | analysis, 75–77 |
| selenomethionine analysis, 76–77 | human selenium supplementation, 91–92, |
| PRP see proline-rich polypeptides | 100 |
| Prunus davidiana, 294 | introduction, 74 |
| Purple coneflower see Echinacea | isomers, 75, 97–98 |
| Purslane, 313 | metabolism, 86–91 |
| Pushkarmool, 309 | natural occurrence and biosynthesis, 77-82 |
| | |

| | T |
|--|---|
| properties, 74–75 | Tocotrienols, 282 |
| proteins and enzymes containing, 82–86 | Toxicity, Se/Se-compounds, 74, 78, 94–100 |
| Se and recommended dietary intakes, | Toxicology, Echinacea, 159–161 |
| 101–102 | Transglutaminase, 42–45, 53 |
| Se yeast as animal feed supplement, 92–94 | Tremella fuciformis, 297 |
| synthesis, 77 | Triglyceride-rich lipoproteins (TRLPs), 279 |
| toxicity, 74, 94–100 | Trigonella foenumgraecum, 310-311 |
| Selenosis, 100 | Trypsin, 54–57 |
| see also selenomethionine toxicity | Tumor necrosis factors (TNF), 149-150, |
| SeMet see selenomethionine | 152–153 |
| SHR see spontaneously hypertensive rat | Turmeric, 308–309 |
| Side effects, Echinacea, 160–161 | |
| Silybum marianum, 316–317 | ${f U}$ |
| Site-directed mutagenesis, 54-57 | UF see ultrafiltration |
| Sitostanol, 282, 289-290 | Ultra high temperature (UHT) treatment, 185 |
| Sitosterols, 282, 287, 289-291 | Ultrafiltration (UF), 237, 239, 241 |
| Solubility | Unsaturated fatty acids, 284, 296 |
| esterification of milk proteins, 17–23 | Upper respiratory infections (URI), 156–159 |
| β-lactoglobulin after glycation, 30–32 | Uptake of selenomethionine, 85–86 |
| proteolytic modification, 38 | URI see upper respiratory infections |
| Soybean protein, 204, 282, 295–296, 314–315 | ord see upper respiratory infections |
| Spirulina, 297 | \mathbf{v} |
| Spontaneously hypertensive rat (SHR), 232–234 | Vaccinium myrtillus, 314 |
| Squalene, 291 | Vanillic acids, 133 |
| = | |
| Standardization, Echinacea, 144–145 | Very low density lipoproteins (VLDL), |
| Statins, 280 Starala, 282, 284, 287, 280, 202 | 280–281, 294, 296 |
| Sterols, 282, 284–287, 289–292 | Viruses, 25–27, 154–155, 186–187 |
| Stigmasterol, 286, 289 | Vitamin C, 150 |
| Succinylation, 3 | Vitis vinifera, 313 |
| Sugars, 27–35 | VLDL see very low density lipoproteins |
| Sulfur-containing compounds, 282, 285, 298 | |
| Supplementation, selenomethionine, 74, 91–94, | W |
| 100 | Wheat gluten, 212 |
| Sweet-tasting proteins, 203–204 | Whey, 30, 52–53 |
| | Whey proteins |
| T | see also individual proteins; milk proteins |
| Tannins, 205 | antihypertensive effect, 182 |
| Tartaric acids, 116 | bioactive peptides and proteins, 177, 180–202 |
| Taste, 205, 226-227 | cancer inhibition, 180–181 |
| Tea polyphenolics, 283, 294-295 | cariostatic effects, 50 |
| Teeth, 237 | emulsifying properties, 17 |
| Terminalia arjuna, 309-310 | food formulations, 51 |
| Theaflavins, 294–295 | limited proteolysis, 39, 40 |
| Thermal structural modifications, whey proteins, | opioid peptides, 208, 211-212 |
| 35–37 | technological production processes, 237–239 |
| Thermostability, β-lactoglobulin, 51–52 | thermal structural modifications, 35–37 |
| Thiocyanate anion, 189, 190 | , |
| Thuja occidentalis, 150 | Y |
| Tissues, selenomethionine, 83–85, 88–90 | Yeast see Se yeast |
| TNF see tumor necrosis factors | Yoghurt, 44, 52–53 |